Stocche Forbes advised JASC Renda Varejo Fundo de Investimento Imobiliário, a real estate investment fund from Genesis Capital, on the acquisition of two real properties in the State of Pernambuco. The transaction value was
Tags :Machado Meyer
Machado Meyer advised on the public offering of the 5th issuance of debentures by Vidroporto, in the total amount of R$ 300 million. The notes were guaranteed by a corporate guarantee granted by Indústria Vidreira
Machado Meyer act as deal counsel on the public offering of the 1st issuance of commercial papers, in a single series, issued by Concessionária VLT Carioca, in the total amount of BRL 72 million. Machado
Machado Meyer Advogados advised Banco Santander (Brasil) on the acquisition of all the shares of Toro Participações, which was advised by BMA and Azevedo Sette Advogados. Once the transaction is in place, Santander will
Machado Meyer acted as deal counsel on the 1st issue of commercial papers, in a single series, for public distribution, under firm guarantee of placement, according to the CVM 160, of Superfrio Armazéns Gerais, in
Machado Meyer advised the issuer and FLH Advogados acted as legal counsel for Banco Credit Agricole Brasil, lead underwriter, in 3rd issue of simple debentures of Administradora Geral de Estacionamentos (Indigo), in the amount of
Different firms have advised HDI International and HDI Seguros (part of the Talanx Group) on the acquisition of Liberty Mutual Insurance’s personal and commercial insurance business in Chile, Brazil, Colombia and Ecuador. The acquisition
Machado Meyer advised Inter&Co, Inc; Unidas Locações e Serviços; Aço Verde do Brasil; on the update of their Reference Form for purposes of annual reporting to the Brazilian Securities Commission (
Machado Meyer acted as deal counsel on the 1st issue of commercial papers, in a single series, for public distribution, according to the CVM 160, of Maxxima Energia, in the total amount of BRL 50 million. Machado
Machado Meyer Advogados acted as legal counsel to Neuraxpharm, a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, in the acquisition of equity interest representing 100% of the capital
